As a member of DANSK BIOTEK you are invited to participate in this survey mapping patient stratification strategies currently undertaken by industry developed by EATRIS, in the context of the PERsonalised MedicIne Trials (‘PERMIT’) project.
The results of the survey will enable a better understanding of the challenges and opportunities in the translational development phase of personalised medicine clinical trials. The retrieved information will be discussed during a workshop in which field experts and key stakeholders will develop recommendations for the establishment of industry-based translational strategies in personalised medicine.
About the project
Launched in January 2020, the H2020-funded PERMIT will develop recommendations for robust and reproducible personalised medicine research. The objective of PERMIT is to establish, with all relevant stakeholders and invited experts, recommendations ensuring the robustness of personalised medicine trials, which also requires validation of the stratification methods. PERMIT brings together field experts, funding bodies, patient representative associations, medicine agencies, HTA authorities, and other key stakeholders from across Europe to collaborate in every stage of the project. The goal is to reach consensus and broad acceptability of the proposed methodological recommendations.
PERMIT is coordinated by the European Clinical Research Infrastructure Network (ECRIN) and has received funding from Horizon 2020 under grant agreement number 874825.
The survey is open until November 9th 2020 and can be accessed by the ‘Read more’ link below. Should you have any questions relating to the survey, please contact Emanuela Oldoni, Biomarker Platform Manager, at email@example.com.